October 2nd 2012
Biosensia’s CEO Diarmuid Flavin to present ‘RapiPlex’ point of care platform at the Advamed 2012 Medtech conference in Boston.
Biosensia will be presenting at the Advamed Medtech Conference at the Boston Convention and Exhibition Centre, October 2nd & 3rd 2012.
Biosensia Ltd., a point of care diagnostics Company, will be demonstrating RapiPlex, its point of care diagnostics platform. Headquartered in Nova, University College Dublin, Ireland, Biosensia is poised to become a major player in the development of next-generation, point of care diagnostics.
RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications including acute phase diagnostics, prognostic diagnostic panels and companion diagnostics at the point of care. RapiPlex enables the transition of complex immunoassays from the central laboratory to the point of care across a wide variety of samples types.
Diarmuid Flavin, CEO, is delighted to be presenting at Advamed. According to Diarmuid “Since Biosensia began commercializing its ‘RapiPlex’ platform we’ve seen substantive market demand across a range of diagnostic applications. Our selection to present at Advamed is a great opportunity for Biosensia as it will afford customers and investors the opportunity to learn more about our company, our technology, and the solutions we offer”.